Estimating the duration of seropositivity of human seasonal coronaviruses using seroprevalence studies [version 2; peer review: 3 approved]

Background: The duration of immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still uncertain, but it is of key clinical and epidemiological importance. Seasonal human coronaviruses (HCoV) have been circulating for longer and, therefore, may offer insights into the lon...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eleanor M. Rees, Naomi R. Waterlow, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Rachel Lowe, Adam J. Kucharski
Formato: article
Lenguaje:EN
Publicado: Wellcome 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/cac32fb1c896401aa428364d6e44ea46
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Background: The duration of immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still uncertain, but it is of key clinical and epidemiological importance. Seasonal human coronaviruses (HCoV) have been circulating for longer and, therefore, may offer insights into the long-term dynamics of reinfection for such viruses. Methods: Combining historical seroprevalence data from five studies covering the four circulating HCoVs with an age-structured reverse catalytic model, we estimated the likely duration of seropositivity following seroconversion. Results: We estimated that antibody persistence lasted between 0.9 (95% Credible interval: 0.6 - 1.6) and 3.8 (95% CrI: 2.0 - 7.4) years. Furthermore, we found the force of infection in older children and adults (those over 8.5 [95% CrI: 7.5 - 9.9] years) to be higher compared with young children in the majority of studies. Conclusions: These estimates of endemic HCoV dynamics could provide an indication of the future long-term infection and reinfection patterns of SARS-CoV-2.